The link you have chosen leads to a site maintained by a third party over whom Bracco Imaging has no control. As such, Bracco Imaging makes no representation as to the accuracy or any other aspect of the information on this site. The clinical use of Bracco Imaging Products in these pages may not be consistent with the approved indications.
The information on this site is not country specific and may contain information that is outside the approved indication where you practice.
Please contact your local Bracco Imaging representative for the latest Bracco Imaging product information specific to your country.
HEALTHCARE PROFESSIONAL DISCLAIMER
This section is intended fo Healthcare professional Audiences only.
I am a Healthcare Professional
ProHance® is a macrocyclic, non-ionic gadolinium-based contrast agent, characterized by very low osmolality and viscosity5.
Due mainly to its macrocyclic structure, ProHance® possesses high in vitro stability2,3.
Furthermore, in the latest clinical studies in patients undergoing total hip arthroplasty, it was shown that the retention of gadolinium in bone tissue was significantly higher in patients receiving Omniscan than in those receiving ProHance®: an approximately 2.5-fold higher gadolinium residue was observed in bone tissue of the femoral head after Omniscan than after ProHance® 4,5.
Clinical experience with ProHance® exceeds 15 million doses administered worldwide6.
ACIST
ACIST® Medical Systems is a market leader in advanced contrast imaging systems for cardiovascular angiography.
ESOR
The European School of Radiology (ESOR) is an apolitical, non-profit, established and a growing project, founded in December 2005.
DISCLAIMER
For any type of product, whether drug or device, mentioned on this website, physicians should carefully review the accompanying documentation, instructions or user manual before administering it to the patient to ensure proper use. Data on the characteristics of Bracco Imaging's main products are available online.
Renal function impairment
Cases of Systemic Nephrogenic Fibrosis (NSF) have been reported associated with the use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30ml/min/1.73m2): as there is a possibility of NSF occurring with ProHance, it should only be used in this type of patients after careful prior evaluation. In patients receiving haemodialysis therapy, haemodialysis may be useful immediately after ProHance administration to remove residual ProHance from the body.